Treatment of Tourette syndrome with cannabinoids

Behavioural Neurology

Volumn 27, Issue 1, 2013, Pages 119-124

  Müller Vahl, Kirsten R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cannabinoids; cannabis sativa; THC; tics; Tourette syndrome

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; AMISULPRIDE; ANANDAMIDE; ARIPIPRAZOLE; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; DRONABINOL; HALOPERIDOL; IODINE 123; NABIXIMOLS; PLACEBO; RISPERIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHMA; ATAXIA; ATTENTION DEFICIT DISORDER; CHEERFULNESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LOW DRUG DOSE; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; NEUROPSYCHOLOGICAL TEST; NOISE SENSITIVITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESSNESS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPASTICITY; SYMPTOM; TIC; TRANSCRANIAL MAGNETIC STIMULATION; XEROSTOMIA;

DRONABINOL; HUMANS; PSYCHOTROPIC DRUGS; TOURETTE SYNDROME;

EID: 84876923962     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.1155/2013/294264     Document Type: Article

References (38)

1. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011; 20(4): 173-96.
2. Mantel BJ, Meyers A, Tran QY, Rogers S, Jacobson JS. Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol. 2004; 14(4): 582-9.
3. Müller-Vahl KR, Buddensiek N, Geomelas M, Emrich HM. The influence of different food and drink on tics in Tourette syndrome. Acta Paediatr. 2008; 97(4): 442-6.
4. Müller-Vahl KR, Kolbe H, Dengler R. Alcohol withdrawal and Tourette's syndrome. Neurology. 1997; 48(5): 1478-9.
5. Müller-Vahl KR, Kolbe H, Dengler R. [Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms]. Nervenarzt. 1997; 68(12): 985-9.
6. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008; 13(2): 147-59.
7. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012; 109(29-30): 495-501.
8. Sandyk R, Awerbuch G. Marijuana and Tourette's syndrome. J Clin Psychopharmacol. 1988; 8(6): 444-5.
9. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol. (Oxford) 1993; 7(4): 389-91.
10. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabi-noids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 1998; 98(6): 502-6.
11. Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabi-nol. Am J Psychiatry. 1999; 156(3): 495.
12. Harcherik DF, Leckman JF, Detlor J, Cohen DJ. A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Psychiatry. 1984; 23(2): 153-60.
13. Müller-Vahl K, Schneider U, Emrich H. Combined treatment of Tourette-Syndrome with delts-9-THC and dopamine receptor antagonists. J Cannabis Therap. 2002; 2: 145-54.
14. Moss DE, Manderscheid PZ, Montgomery SP, Norman AB, Sanberg PR. Nicotine and cannabinoids as adjuncts to neu-roleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci. 1989; 44(21): 1521-5.
15. Brunnauer A, Segmiller FM, Volkamer T, Laux G, Müller N, Dehning S. Cannabinoids improve driving ability in a Tourette's patient. Psychiatry Res. 2011; 190(2-3): 382.
16. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989; 28(4): 566-73.
17. Strohbeck-Kühner P, Skopp G, Mattern R. [Fitness to drive in spite (because) of THC]. Arch Kriminol. 2007; 220(1-2): 11-9.
18. Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report. J Clin Psychopharmacol. 2010; 30(2): 190-2.
19. Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002; 35(2): 57-61.
20. Leckman J, Towbin K, Ort S, Cohen D. Clinical assessment of tic disorder severity. In: Cohen D, Bruun R, Leckman J, editors. Tourette's syndrome and tic disorders. New York: John Wiley; 1988.
21. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull. 1973; 9(1): 13-28.
22. Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003; 64(4): 459-65.
23. Shapiro A, Shapiro E, Young J, Feinberg T. Signs, symptoms, and clinical course. In: Shapiro A, Shapiro E, Young J, Feinberg T, editors. Gilles de la Tourette Syndrome. 2nd ed. New York: Raven Press; 1988; p. 127-93.
24. Goetz CG, Tanner CM, Wilson RS, Shannon KM. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology. 1987; 37(9): 1542-4.
25. Müller-Vahl KR, Koblenz A, Jöbges M, Kolbe H, Emrich HM, Schneider U. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry. 2001; 34(1): 19-24.
26. Helmstaedter C, Lendt M, Lux S. VLMT-verbaler Lern-und Merkfähigkeitstest. Beltz Test GmbH, Hogrefe Verlag; 2001.
27. Benton AL. A visual retention test for clinical use. ArchNeurol Psychiatry. 1945; 54: 212-6.
28. Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg; 1989.
29. Merz J, Lehrl S, Galster J, Erzigkeit H. MWT-B-ein Intelligenzkurztest. Psychiatr Neurol Med Psychol. 1975; 27: 423-8.
30. Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacolo- gy. 2003; 28(2): 384-8.
31. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: A review. Curr Drug Abuse Rev. 2008; 1(1): 81-98.
32. Joy B, Watson SJ, Benson JA, Jr. Marijuana and Medicine. Division of Neuroscience and Behavioral Health [Internet]. Washington, D.C.: National Academy Press; 1999 [cited 2012 Sep 7]. Available from: http://www.nap.edu/ openbook.php? recordid=6376.
33. Klosterkötter J. Indicated prevention of schizophrenia. Dtsch Arztebl Int. 2008; 105(30): 532-9.
34. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. U.S.A. [Internet]. 2012 Aug 27 [cited 2012Sep 11]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22927402.
35. Berding G, Müller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, et al. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry. 2004; 55(9): 904-15.
36. Gadzicki D, Müller-Vahl KR, Heller D, Ossege S, Nöthen MM, Hebebrand J, et al. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet. 2004; 127B(1): 97-103.
37. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev. 2009; (4): CD006565.
38. Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012; 57(3): 133-43.